Biomaxima (FRA:944) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:944 Biomaxima SA FRA:944
50 GF Score
Price €1.98
GF Value €2.94
! 4 Warning Signs
View Full Analysis

What is Biomaxima Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:944
50GF Score
Biomaxima SA FRA:944
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biomaxima (FRA:944) Overvalued in 2026?

Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued. The current stock price of €1.98 is trading 32.7% below its estimated GF Value™ of €2.94.

Key valuation signals for FRA:944:

  • Dividends Received:
  • GF Value™: €2.94 vs. price of €1.98 (32.7% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biomaxima Business Description

Other Exchanges BMX:Poland
Address 5 Vetterow Street, Lublin, POL, 20-277
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
50GF Score

Get the complete analysis for FRA:944

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.98
Price
€2.94
GF Value